Core Viewpoint - Altria Group, Inc. is expected to report a decline in revenues for Q2 2025, while earnings are projected to show growth compared to the previous year [1][9]. Revenue and Earnings Estimates - The Zacks Consensus Estimate for Q2 revenues is $5.2 billion, reflecting a 1.7% decrease from the same period last year [1]. - The consensus estimate for earnings per share (EPS) has increased to $1.37, indicating a 4.6% growth year-over-year [1][9]. Earnings Performance and Predictions - Altria has a trailing four-quarter average earnings surprise of 1.3%, with the last quarter's earnings exceeding the Zacks Consensus Estimate by 5.1% [2]. - The company currently has an Earnings ESP of +1.03% and a Zacks Rank of 3 (Hold), suggesting a potential earnings beat [4][3]. Factors Influencing Q2 Earnings - Regulatory pressures, particularly the ITC's exclusion order on NJOY ACE, have negatively impacted Altria's smoke-free product portfolio [5]. - The cigarette business is facing volume pressures due to consumer downtrading and competition from illicit flavored disposable vapes [5]. - Despite these challenges, Altria's strong pricing power and cost control measures are expected to support profitability [6][7]. Stock Performance - Over the past three months, Altria's stock has increased by 2.6%, slightly below the Zacks Tobacco industry's growth of 2.7% and significantly trailing the S&P 500's 15.5% rise [8]. - Altria's stock performance has outpaced Philip Morris International, which declined by 6.8%, but underperformed Turning Point Brands and British American Tobacco [8]. Valuation Analysis - Altria shares are trading at a forward 12-month price-to-earnings (P/E) ratio of 10.96, below the industry average of 14.48, indicating attractive value for investors [11]. - Compared to key competitors, Altria's P/E ratio is significantly lower than Philip Morris International (20.11) and Turning Point Brands (21.54), while being comparable to British American Tobacco (10.94) [13]. Investment Outlook - Altria faces a mixed backdrop with regulatory challenges and volume pressures, but resilient pricing power and disciplined cost control may provide stability [14]. - Investors may consider holding positions or selectively adding to their investments, while monitoring management's updates on product pipeline and strategic execution [14].

Core Insights - The tobacco sector presents two main investment options: Altria Group, Inc. and Philip Morris International Inc., each with distinct market strategies and growth trajectories towards a smoke-free future [1][2] Altria Group, Inc. - Altria focuses on the U.S. market, leveraging its Marlboro brand while expanding into alternatives like NJOY and oral nicotine pouches [2] - The company achieved a 10.8% net price realization in smokeable products in Q1 2025, contributing to a 2.7% increase in adjusted operating income [3][9] - Altria's oral nicotine pouch brand, on!, saw an 18% increase in shipments, capturing 8.8% of the oral tobacco category and 17.9% of the nicotine pouch segment [4][9] - Despite setbacks in the e-vapor category, Altria is refining its product pipeline and advocating for regulatory reforms to combat the rise of illicit disposable e-vapor products, which account for over 60% of the U.S. market [5] - The cigarette industry faces challenges, with shipment volumes declining due to macroeconomic pressures and the growth of illegal e-vapor products, impacting low-income smokers [6] Philip Morris International Inc. - Philip Morris is advancing its transformation strategy with a strong smoke-free portfolio, including IQOS, ZYN, and VEEV, and has approximately 41.5 million adult users by Q2 2025 [7][9] - IQOS is the primary driver of growth, with accelerated adoption in key markets supported by commercial initiatives and product innovations [8][10] - The company offers smoke-free products in 97 markets, with nearly half providing multiple product categories, enhancing its global reach [10] - Philip Morris faces challenges such as currency volatility and increasing regulatory risks, particularly regarding nicotine pouch marketing [11] Financial Performance and Valuation - Altria's forward P/E ratio is 10.96, appealing to income-focused investors, while Philip Morris has a higher multiple of 20.12, reflecting its global presence and momentum in smoke-free products [15] - Over the past month, Altria gained 2.1%, while Philip Morris dropped 11.6%, underperforming the S&P 500's 3.4% rise [14] Conclusion - Philip Morris is better positioned for long-term growth with its aggressive pivot towards a smoke-free future and strong global traction, while Altria's focus on domestic stability and pricing strength supports income-focused investors but faces more headwinds [16]

Core Insights - Altria Group, Inc. (MO) has achieved a 21.2% gain over the past six months, outperforming the Zacks Consumer Staples sector's growth of 10.7% and the S&P 500's advance of 6.3% [1] - The stock is trading near its 52-week high of $60.25, just 1.6% below the peak reached on May 7, 2025, indicating strong upward momentum [4] - Altria's strong performance is attributed to robust pricing power in its core combustible tobacco segment, particularly with its flagship brand, Marlboro, which commands a 10.8% net price realization [8][9] Performance Comparison - Altria's stock performance is strong relative to major tobacco players, with Philip Morris International Inc. (PM) surging 51.2%, Turning Point Brands, Inc. (TPB) gaining 28.5%, and British American Tobacco p.l.c. (BTI) increasing by 37% over the same period [3] - The stock's position above key technical benchmarks, including the 50-day and 200-day moving averages, suggests sustained bullish momentum [4][5] Financial Metrics - Altria repurchased 5.7 million shares and paid $1.7 billion in dividends in the first quarter of 2025, reinforcing its commitment to shareholder returns [6][12] - The company's forward 12-month P/E ratio is 11.03, which is attractive compared to the industry average of 15.28, positioning Altria as a compelling value opportunity [13][15] Growth Drivers - The Marlboro brand expanded its share of the premium category to 59.3% in the first quarter, supported by advanced Revenue Growth Management tools [9] - Altria's smoke-free product line, particularly the oral nicotine pouch brand on!, saw an 18% increase in shipments, capturing 8.8% of the oral tobacco category and 17.9% of the nicotine pouch segment [10] - The company is addressing regulatory challenges in the e-vapor category and is committed to refining its product pipeline for future market re-entry [11] Investment Outlook - Altria's combination of strong pricing power, growth in smoke-free products, and a proactive approach to regulatory challenges positions it well for long-term performance [18] - The stock is viewed as a solid opportunity for value and income-focused investors, particularly given its discounted valuation and attractive dividend yield [18]

Core Insights - Altria Group, Inc. is committed to transitioning towards a smoke-free future, with a focus on its oral tobacco portfolio, particularly the on! nicotine pouch brand, which has shown significant growth in shipment volumes and market share [1][2][9] - The company's oral tobacco revenues increased by 0.5% to $654 million in Q1 2025, driven by pricing power despite macroeconomic challenges [2] - Altria faces challenges in the vapor segment, particularly after regulatory issues led to the discontinuation of its NJOY ACE product, but plans to introduce compliant alternatives [3][4] Oral Tobacco Performance - The on! nicotine pouch brand's shipment volumes rose 18% year-over-year, exceeding 39 million cans, and its market share in the oral tobacco category increased by 1.8 percentage points to 8.8% [1][9] - The nicotine pouch market share for on! reached 17.9%, indicating strong consumer loyalty and brand strength despite retail price increases [1] Vapor Segment Challenges - Regulatory setbacks have impacted Altria's vapor products, leading to the discontinuation of NJOY ACE, but the company is working on launching new compliant products to regain market share [3][4] Competitive Landscape - Altria competes with Philip Morris International and British American Tobacco in the smoke-free category, both of which are also focusing on reduced-risk products [5][6][7] - Philip Morris reported a 20.4% increase in net revenues and a 33.1% rise in smoke-free gross profit, with significant growth in its ZYN and VEEV products [6] - British American Tobacco aims for 50 million consumers by 2030 and reported a 2.5% increase in New Category revenues in 2024 [7] Financial Performance and Valuation - Altria's stock has gained 12.5% year-to-date, while the industry has grown by 37.7% [8] - The company trades at a forward price-to-earnings ratio of 10.76X, below the industry average of 15.36X [11] - Earnings estimates for 2025 and 2026 suggest year-over-year growth of 4.9% and 3.3%, respectively, with recent upward revisions [12]

Market Overview - U.S. stock markets experienced significant volatility in the first half of 2025, contrasting with the smooth rally of the previous two years, primarily due to tariffs imposed by the Trump administration, inflation fears, and concerns over U.S. AI companies [1] - Recent positive developments in global tariffs, a declining inflation rate, and favorable economic data have led to a recovery in Wall Street, alleviating recession fears [2] Geopolitical Factors - The U.S.-China trade deal remains unfinalized, contributing to ongoing market fluctuations, alongside geopolitical tensions in the Middle East and the prolonged conflict between Russia and Ukraine [3] Consumer Staples Sector - The consumer staples sector is characterized as mature and fundamentally strong, with demand for essential products being relatively immune to economic cycles, making it a defensive investment choice [5][6] - This sector is known for stable earnings and cash flows, providing a safe haven for investors during market volatility [6] Recommended Stocks - Investment in defensive stocks like consumer staples is advised to stabilize portfolios, with five high-dividend paying stocks recommended: Philip Morris International Inc. (PM), The Coca-Cola Co. (KO), Mondelez International Inc. (MDLZ), Altria Group Inc. (MO), and Corteva Inc. (CTVA) [4] Company Performance Philip Morris International Inc. (PM) - PM anticipates 2025 volume growth, with smoke-free products projected to rise by 12-14%, aiming for substantial smoke-free status by 2030 [10][11][12] - Expected revenue and earnings growth rates for PM are 8.1% and 13.7%, respectively, with a current dividend yield of 2.94% [13] The Coca-Cola Co. (KO) - Coca-Cola reported its ninth consecutive earnings beat in Q1 2025, driven by broad-based growth and effective execution of its all-weather strategy [14][15] - Expected revenue and earnings growth rates for KO are 2.5% and 3.1%, respectively, with a current dividend yield of 2.93% [15] Mondelez International Inc. (MDLZ) - Mondelez achieved 3.1% organic revenue growth in Q1 2025, supported by strategic pricing and strong performance in core categories [16][17] - Expected revenue and earnings growth rates for MDLZ are 5.3% and -10.1%, respectively, with a current dividend yield of 2.83% [18] Altria Group Inc. (MO) - Altria's first-quarter results were bolstered by pricing power despite weaker volumes, particularly in the smokeable product unit [19][20] - Expected revenue and earnings growth rates for MO are -1.4% and 5.3%, respectively, with a current dividend yield of 6.92% [21] Corteva Inc. (CTVA) - Corteva operates in agriculture, focusing on seed development and crop protection, with operations across multiple regions [22][23][24] - Expected revenue and earnings growth rates for CTVA are 2.5% and 16.3%, respectively, with a current dividend yield of 0.92% [25]

Core Viewpoint - Altria Group Inc. experienced a 2.1% decline in share price following the release of its first-quarter 2025 results, contrasting with slight gains in the broader market and its industry peers [1][6]. Financial Performance - Altria reported first-quarter adjusted earnings per share (EPS) of $1.23, exceeding the Zacks Consensus Estimate of $1.17, reflecting a 6% year-over-year growth [6]. - Net revenues fell by 5.7% to $5.26 billion, primarily due to weaker cigarette shipment volumes [6][9]. - The Zacks Consensus Estimate for Altria's EPS for 2025 and 2026 has increased by 0.8% and 1.1%, respectively, indicating a positive outlook [12]. Market Comparison - Among tobacco peers, Turning Point Brands, Inc. outperformed with a 17.9% return, while Philip Morris International and British American Tobacco saw declines of 2.5% and 3.3%, respectively [2]. - Altria's forward 12-month price-to-earnings (P/E) ratio is 10.51x, significantly lower than the industry average of 14.55x and the S&P 500's average of 20.70x, suggesting it is undervalued [15][16]. Business Segments - Altria's Smokeable Products segment faced revenue softness due to declining shipment volumes, but robust pricing strategies helped mitigate margin erosion [8][9]. - The oral nicotine pouch brand on! saw an 18% increase in shipment volumes, reaching over 39 million cans, and expanded its market share in the nicotine pouch segment to 17.9% [10]. - The e-vapor segment faced challenges with the discontinuation of NJOY ACE, resulting in a non-cash impairment charge of $873 million, but the company remains committed to innovation in this space [11]. Investor Sentiment - The divergence between solid earnings performance and stock price weakness raises questions about whether the pullback is a short-term overreaction or a long-term buying opportunity [7]. - Altria's defensive business model and attractive valuation make it a stable investment option, especially for value-focused investors [19].